{"id":"https://openalex.org/W2144610076","doi":"https://doi.org/10.3109/10428194.2012.695781","title":"Targeting the B cell receptor pathway in chronic lymphocytic leukemia","display_name":"Targeting the B cell receptor pathway in chronic lymphocytic leukemia","publication_year":2012,"publication_date":"2012-05-23","ids":{"openalex":"https://openalex.org/W2144610076","doi":"https://doi.org/10.3109/10428194.2012.695781","mag":"2144610076","pmid":"https://pubmed.ncbi.nlm.nih.gov/22616724","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4557770"},"language":"en","primary_location":{"id":"doi:10.3109/10428194.2012.695781","doi":"https://doi.org/10.3109/10428194.2012.695781","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10428194.2012.695781","pdf_url":null,"source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4557770","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["CLL Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CLL Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":["CLL Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CLL Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5016570475"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"],"apc_list":null,"apc_paid":null,"fwci":2.0752,"has_fulltext":false,"cited_by_count":82,"citation_normalized_percentile":{"value":0.89594972,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"53","issue":"12","first_page":"2362","last_page":"2370"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/b-cell-receptor-signaling","display_name":"B cell receptor signaling","score":0.9129999876022339},{"id":"https://openalex.org/keywords/spleen-tyrosine-kinase-inhibitor","display_name":"spleen tyrosine kinase inhibitor","score":0.8799999952316284},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9120000004768372},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9229999780654907},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7639999985694885},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.9679999947547913},{"id":"https://openalex.org/keywords/17p-deletion","display_name":"17p deletion","score":0.7609999775886536},{"id":"https://openalex.org/keywords/zap-70","display_name":"ZAP-70","score":0.8349999785423279},{"id":"https://openalex.org/keywords/ccl3","display_name":"CCL3","score":0.9520000219345093},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.6259999871253967},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.44600000977516174}],"concepts":[{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.8208876848220825},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.8138086795806885},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.8091920614242554},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.8064402937889099},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6709839701652527},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.630084753036499},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.6044641137123108},{"id":"https://openalex.org/C43907098","wikidata":"https://www.wikidata.org/wiki/Q903924","display_name":"breakpoint cluster region","level":3,"score":0.5636695027351379},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.544651210308075},{"id":"https://openalex.org/C157695867","wikidata":"https://www.wikidata.org/wiki/Q1100474","display_name":"B-cell receptor","level":4,"score":0.5081660747528076},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.44199687242507935},{"id":"https://openalex.org/C2777609679","wikidata":"https://www.wikidata.org/wiki/Q5971015","display_name":"IGHV@","level":4,"score":0.43480533361434937},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.42502203583717346},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4015161395072937},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3726802468299866},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.35903310775756836},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3263154625892639},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.28804194927215576},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1931588053703308},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.17649158835411072},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17602896690368652},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.0},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000072377","descriptor_name":"Syk Kinase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011947","descriptor_name":"Receptors, Antigen, B-Cell","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019869","descriptor_name":"Phosphatidylinositol 3-Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D047908","descriptor_name":"Intracellular Signaling Peptides and Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D047908","descriptor_name":"Intracellular Signaling Peptides and Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.3109/10428194.2012.695781","doi":"https://doi.org/10.3109/10428194.2012.695781","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10428194.2012.695781","pdf_url":null,"source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},{"id":"pmid:22616724","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22616724","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & lymphoma","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:3535938","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4557770","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4557770","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4557770","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Leuk Lymphoma","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3535938","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4557770","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[{"id":"https://openalex.org/G9000877998","display_name":"Physician Scientist Training in Cancer Research","funder_award_id":"T32CA009172","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":68,"referenced_works":["https://openalex.org/W127796594","https://openalex.org/W1429374962","https://openalex.org/W1580240122","https://openalex.org/W1912693401","https://openalex.org/W1914062369","https://openalex.org/W1970102311","https://openalex.org/W1970663543","https://openalex.org/W1972593274","https://openalex.org/W1976058906","https://openalex.org/W1976174817","https://openalex.org/W1976248184","https://openalex.org/W1976402300","https://openalex.org/W1983579522","https://openalex.org/W1984147944","https://openalex.org/W1993355130","https://openalex.org/W1993986769","https://openalex.org/W2004264801","https://openalex.org/W2007973857","https://openalex.org/W2011950935","https://openalex.org/W2015062933","https://openalex.org/W2019216438","https://openalex.org/W2019655196","https://openalex.org/W2025786205","https://openalex.org/W2026096732","https://openalex.org/W2026234361","https://openalex.org/W2027971058","https://openalex.org/W2031121711","https://openalex.org/W2033315156","https://openalex.org/W2036758696","https://openalex.org/W2038053631","https://openalex.org/W2040604274","https://openalex.org/W2055091448","https://openalex.org/W2065338378","https://openalex.org/W2067630156","https://openalex.org/W2070232733","https://openalex.org/W2075875145","https://openalex.org/W2076274224","https://openalex.org/W2076690627","https://openalex.org/W2078161165","https://openalex.org/W2086800018","https://openalex.org/W2087947799","https://openalex.org/W2095726706","https://openalex.org/W2103820395","https://openalex.org/W2107469531","https://openalex.org/W2107615815","https://openalex.org/W2107821023","https://openalex.org/W2108131308","https://openalex.org/W2119374469","https://openalex.org/W2121510983","https://openalex.org/W2128631476","https://openalex.org/W2143790526","https://openalex.org/W2145842706","https://openalex.org/W2154992334","https://openalex.org/W2159403435","https://openalex.org/W2160009436","https://openalex.org/W2163690533","https://openalex.org/W2168215118","https://openalex.org/W2170865316","https://openalex.org/W2172393633","https://openalex.org/W2242208648","https://openalex.org/W2243971624","https://openalex.org/W2286779516","https://openalex.org/W2312290384","https://openalex.org/W2534353580","https://openalex.org/W2573662645","https://openalex.org/W2584629017","https://openalex.org/W2942513871","https://openalex.org/W2980158349"],"related_works":["https://openalex.org/W1986389899","https://openalex.org/W4394893534","https://openalex.org/W2032553162","https://openalex.org/W2314927220","https://openalex.org/W2187874122","https://openalex.org/W2143413057","https://openalex.org/W2087647272","https://openalex.org/W7096561225","https://openalex.org/W2011782763","https://openalex.org/W2100751415"],"abstract_inverted_index":{"The":[0],"B":[1],"cell":[2,57],"receptor":[3],"(BCR)":[4],"pathway":[5,89,138],"plays":[6],"a":[7,111],"crucial":[8],"role":[9],"in":[10,27,51,79,84,96,187],"the":[11,24,66,129,132,134,143,161,188],"survival,":[12],"proliferation":[13],"and":[14,43,61,139,152,176,178],"trafficking":[15],"of":[16,23,37,65,73,100,114,131,156,163,191],"chronic":[17],"lymphocytic":[18],"leukemia":[19],"(CLL)":[20],"cells.":[21],"Inhibitors":[22],"key":[25],"kinases":[26,75,135],"this":[28,137],"pathway,":[29],"including":[30],"spleen":[31],"tyrosine":[32,45],"kinase":[33,46],"(SYK),":[34],"mammalian":[35],"target":[36],"rapamycin":[38],"(mTOR),":[39],"phosphoinositide":[40],"3'-kinase":[41],"(PI3K)":[42],"Bruton's":[44],"(BTK),":[47],"have":[48,76,109],"been":[49,77],"found":[50],"preclinical":[52],"models":[53],"to":[54,92,168],"decrease":[55],"CLL":[56,144,192],"viability":[58],"both":[59],"directly":[60],"indirectly":[62],"through":[63],"modulation":[64],"microenvironment.":[67,145],"Recently,":[68],"oral":[69],"agents":[70,108,170],"targeting":[71],"each":[72],"these":[74,169,181],"explored":[78],"early":[80,116],"phase":[81],"clinical":[82,154],"trials":[83,155],"patients":[85],"with":[86,123,142],"CLL.":[87],"BCR":[88,157],"antagonists":[90],"appear":[91],"be":[93],"highly":[94],"active":[95],"relapsed/refractory":[97],"CLL,":[98],"independent":[99],"high-risk":[101],"disease":[102],"markers":[103],"such":[104,171],"as":[105,172],"del(17p).":[106],"These":[107],"shown":[110],"unique":[112],"pattern":[113],"inducing":[115],"transient":[117],"lymphocytosis,":[118],"which":[119],"typically":[120],"is":[121],"associated":[122],"nodal":[124],"response.":[125],"Here,":[126],"we":[127],"review":[128],"biology":[130],"BCR,":[133],"within":[136],"their":[140],"interaction":[141],"We":[146,159],"also":[147],"discuss":[148,179],"data":[149],"from":[150],"recent":[151],"ongoing":[153],"antagonists.":[158],"address":[160],"development":[162],"potential":[164],"biomarkers":[165],"for":[166],"response":[167],"ZAP-70,":[173],"IGHV":[174],"status":[175],"CCL3,":[177],"where":[180],"exciting":[182],"new":[183],"drugs":[184],"may":[185],"fit":[186],"evolving":[189],"landscape":[190],"therapy.":[193]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":18},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}